Influenza Vaccination and Hospitalizations Among COVID-19 Infected Adults

References

1. 1.↵
   Johns Hopkins University (JHU). COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at JHU. https://coronavirus.jhu.edu/map.html. Accessed Sept 19, 2020.
2. 2.↵
   1. Garg S,
   2. Kim L,
   3. Whitaker M,
   4. et al

   . Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458–64.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Sultana J,
   2. Mazzaglia G,
   3. Luxi N,
   4. et al

   . Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Rev Vaccines 2020;1–18.
4. 4.↵
   1. Ma Z,
   2. Li P,
   3. Ikram A,
   4. Pan Q

   . Does cross-neutralization of SARS-CoV-2 only relate to high pathogenic Coronaviruses? Trends Immunol 2020;41:851–3.

   OpenUrl
5. 5.↵
   1. Jiang S,
   2. Du L

   . Effect of low-pathogenic human coronavirus-specific antibodies on SARS-CoV-2. Trends Immunol 2020;41:853–4.

   OpenUrl
6. 6.↵
   1. Cowling BJ,
   2. Fang VJ,
   3. Nishiura H,
   4. et al

   . Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. Clin Infect Dis 2012;54:1778–83.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Suzuki M,
   2. Camacho A,
   3. Ariyoshi K

   . Potential effect of virus interference on influenza vaccine effectiveness estimates in test-negative designs. Epidemiol Infect 2014;142:2642–6.

   OpenUrl
8. 8.↵
   1. Wolff GG

   . Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season. Vaccine 2020;38:350–4.

   OpenUrlCrossRef
9. 9.↵
   1. Thindwa D,
   2. Garcia Quesada M,
   3. Liu Y,
   4. et al

   . Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. Vaccine 2020;38:5398–401. 07.

   OpenUrl
10. 10.↵
    National Committee on Quality Assurance. HEDIS measures for flu and vaccinations. 2020. Available at: https://www.ncqa.org/hedis/measures/flu-vaccinations/. Accessed Sept 19, 2020.
11. 11.↵
    1. Gupta T,
    2. Gupta SK

    . Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int Immunopharmacol 2020;86:106717.

    OpenUrlCrossRef
12. 12.↵
    1. Jewett A

    . The potential effect of novel coronavirus SARS-CoV-2 on NK cells; a perspective on potential therapeutic interventions. Front Immunol 2020;11:1692.

    OpenUrl
13. 13.↵
    1. Jost S,
    2. Altfeld M

    . Control of human viral infections by natural killer cells. Annu Rev Immunol 2013;31:163–94.

    OpenUrlCrossRefPubMedWeb of Science